The current financial score of Profound Medical Corp is 6.31. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 2.48M, representing a year-over-year increase of 12.30%, while its net profit experienced a year-over-year increase of 39.22%.
The current valuation score of Profound Medical Corp is 7.69. Its current P/E ratio is -4.71, which is -43.36% below the recent high of -2.66 and -141.62% above the recent low of -11.37.
The current earnings forecast score of Profound Medical Corp is 9.20. The average price target is 11.05, with a high of 12.00 and a low of 10.00.
The current price momentum score of Profound Medical Corp is 5.66. Currently, the stock price is trading between the resistance level at 7.01 and the support level at 5.10, making it suitable for range-bound swing trading.
The current institutional shareholding score of Profound Medical Corp is 3.00. The latest institutional shareholding proportion is 47.52%, representing a quarter-over-quarter increase of 35.25%. The largest institutional shareholder is Chuck Royce, holding a total of 1.20M shares, representing 0.06% of shares outstanding, with 36.34% increase in holdings.
The current risk assessment score of Profound Medical Corp is 3.60. The company's beta value is 0.52. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.